ABVC BioPharma, Inc. reported substantial financial growth in its third quarter 2025 results, with licensing revenue increasing 230% year-over-year and total assets growing 181% since December 2024. The clinical-stage biopharmaceutical company, which develops therapeutic solutions for central nervous system disorders, ophthalmology, and oncology/hematology indications, recognized approximately $1.28 million in licensing revenue for Q3 2025 compared to $0.39 million for the same period in 2024.
The company's total assets reached $21.18 million as of September 30, 2025, up from $7.54 million at the end of 2024. Property and equipment showed the most dramatic growth, increasing approximately 2,100% to $12.06 million from $0.51 million at year-end 2024, primarily due to strategic real-asset investments in Taiwan. These financial metrics indicate ABVC's transition toward a more asset-backed business model while maintaining its core focus on licensing and partnerships.
During the third quarter, ABVC completed two significant land acquisitions in Taiwan totaling approximately $11 million. AiBtl BioPharma Inc., an affiliate company, acquired property in Puli, Nantou for $7.67 million to develop a plant factory for botanical raw materials and new drug substance research. ABVC BioPharma itself acquired land in Longtan, Taoyuan for $3.3 million dedicated to agricultural research and development and API cultivation. These investments, combined with the planned Vitargus® GMP manufacturing facility, are expected to strengthen the company's Asia-based production and research capabilities.
The company maintains what it describes as a global dual-core operational structure, with Silicon Valley operations focusing on innovation and clinical development through its BioKey platform, while Taiwan supports manufacturing and development activities. This strategic approach allows ABVC to leverage the innovation ecosystem of Silicon Valley while benefiting from Taiwan's manufacturing expertise and infrastructure.
ABVC continues to maintain multiple licensing agreements covering its CNS, ophthalmology, and oncology pipelines, each providing potential future milestone and royalty income based on development and commercialization progress. The company follows an asset-light business model focused on licensing, partnerships, and collaborative development, though recent investments in physical assets suggest an evolution toward greater manufacturing control.
The company's pipeline includes six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, ABVC utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center to conduct proof-of-concept trials through Phase II clinical development. For Vitargus®, the company intends to conduct pivotal clinical trials (Phase III) through global partnerships. Investors can find detailed information about the company and risk factors in filings with the Securities and Exchange Commission available at https://www.sec.gov.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the third-quarter results reflect continued progress in both licensing revenue and asset development activities, emphasizing the company's focus on executing strategic priorities to create sustainable long-term shareholder value. The significant growth in both revenue and assets positions ABVC for expanded research capacity and potential acceleration of its therapeutic development programs across multiple medical specialties.
